Ligand ID: DXT


Drugbank ID:
DB00254
(Doxycycline)


Indication:
Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus

Get human targets for DXT in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'DXT'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		1xak ORF7A ACCESSORY
PROTEIN
(SARSr-CoV)		4 / 6
LEU A  41
SER A  29
PHE A  48
HIS A  47
1.44A16.79
18.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
THR G  43
GLN G  47
LEU G  48
ILE H   2
SER I  49
1.61A11.56
None
ACT  H 202 ( 4.2A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
ASN F  27
THR A  21
GLN A  17
ILE A  13
SER F  29
1.78A10.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		4 / 6
LEU C 265
SER C 247
ASP C 248
HIS C 224
1.43A19.58
12.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		5 / 9
VAL A 337
LEU A 308
ALA A 311
VAL A 346
ILE A 200
1.45A20.11
14.29
GOL  A1010 (-3.8A)
None
GOL  A1010 ( 4.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
LEU S 412
PHE S 416
ASP S 415
VAL S 420
ILE S 397
1.52A19.78
12.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		5 / 9
VAL B 156
LEU B 127
ALA B 130
VAL B 165
ILE B  19
1.34A19.84
14.29
APR  B 477 ( 4.9A)
APR  B 477 (-4.7A)
APR  B 477 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		4 / 6
LEU B  84
SER B  66
ASP B  67
HIS B  43
1.40A19.79
11.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2fyg REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		6 / 9
VAL A 108
LEU A  75
ALA A  24
ASP A  22
VAL A  13
ILE A  38
1.53A16.89
11.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2ga6 ORF1A POLYPROTEIN
(SARSr-CoV)		6 / 9
VAL B 108
LEU B  75
ALA B  24
ASP B  22
VAL B  13
ILE B  38
1.37A17.62
14.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2ghv SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
LEU E 412
PHE E 416
ASP E 415
VAL E 420
ILE E 397
1.51A19.41
12.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 12
SER A 273
ASN A  74
PRO A 343
VAL A 275
ILE A 322
1.79A22.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 12
SER A 273
ASN A  74
PRO A 343
LEU A 297
ILE A 322
1.35A21.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2q6g REPLICASE
POLYPROTEIN 1AB
(SARS-COV
BJ01)		5 / 9
VAL B 171
LEU B 167
ALA B 193
PHE B 185
HIS B 134
1.55A21.70
7.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
SER C 273
ASN C  74
PRO C 343
VAL C 275
ILE C 322
1.59A21.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
SER C 273
ASN C  74
PRO C 343
LEU C 297
ILE C 322
1.32A20.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2xyq NSP10
(SARSr)		5 / 9
VAL B 108
LEU B  75
ALA B  24
VAL B  13
ILE B  38
1.39A16.00
12.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.77A21.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2xyr NSP10
(SARSr-CoV)		6 / 9
VAL B 108
LEU B  75
ALA B  24
ASP B  22
VAL B  13
ILE B  38
1.39A16.00
12.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		2xyv NSP10
(SARSr-CoV)		6 / 9
VAL B 108
LEU B  75
ALA B  24
ASP B  22
VAL B  13
ILE B  38
1.42A14.00
9.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		5 / 9
LEU S 412
PHE S 416
ASP S 415
VAL S 420
ILE S 397
1.48A20.23
12.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3d0i ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
ASN B  33
THR B  92
VAL B  93
GLN B  96
LEU B  97
0.88A15.99
None
NDG  B 616 ( 4.6A)
NDG  B 616 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		3ee7 REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 6
LEU B  29
SER B  13
ASP B  26
HIS B 118
1.66A14.48
18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3f9h 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 12
ASN B 119
HIS B  41
THR B  21
VAL B  20
SER B 144
1.69A20.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3i6k BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		5 / 12
PHE B  62
ARG A  17
THR B  86
VAL B  85
ILE B  35
1.75A19.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		3r24 2'-O-METHYL
TRANSFERASE
NSP10 AND NSP11
(SARSr-CoV)		4 / 6
LEU A 111
SER A  98
ASP A  97
HIS B  80
1.77A22.92
8.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		3r24 NSP10 AND NSP11
(SARSr-CoV)		6 / 9
VAL B 108
LEU B  75
ALA B  24
ASP B  22
VAL B  13
ILE B  38
1.43A19.09
13.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3sci ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE E 460
HIS E 445
THR A  20
GLN A  24
SER E 461
1.65A21.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3sci ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE E 460
HIS E 445
THR A  20
GLN A  24
SER E 461
1.63A21.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 12
PHE F 460
HIS F 445
THR B  20
GLN B  24
SER F 461
1.75A20.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3scl ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
ASN A  33
THR A  92
VAL A  93
GLN A  96
LEU A  97
1.05A16.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		3vb5 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 9
VAL B 171
LEU B 167
ALA B 193
PHE B 185
HIS B 134
1.55A21.70
7.82
None
None
None
None
EDO  B 402 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 9
VAL B 171
LEU B 167
ALA B 193
PHE B 185
HIS B 134
1.55A21.99
7.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		5 / 12
SER A 247
PHE A 312
THR A 308
VAL A 307
GLN A 213
1.65A18.89
None
None
None
PO4  A 404 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		5 / 9
LEU A 284
ALA A 265
PHE A 263
VAL A 255
ILE A 289
1.32A24.04
9.12
None
None
PO4  A 404 (-3.7A)
PO4  A 404 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		4tww 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 9
VAL A 171
LEU A 167
ALA A 193
PHE A 185
HIS A 134
1.53A21.70
7.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5b6o 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 9
LEU A 220
ALA A 267
PHE A 219
VAL A 212
ILE A 259
1.56A21.45
7.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5c8s NSP10
(SARSr-CoV)		5 / 9
LEU C  75
ALA C  24
ASP C  22
VAL C  13
ILE C  38
1.27A15.45
17.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 6
LEU D 253
SER D 255
ASP D 258
HIS D 268
1.56A20.39
6.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5c8s GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
SER A  11
ASN A  10
THR B   5
VAL B   4
LEU B  27
1.51A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		4 / 6
LEU D 253
SER D 255
ASP D 258
HIS D 268
1.48A20.36
6.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5c8t GUANINE-N7
METHYLTRANSFERASE
NSP10
(SARSr-CoV)		5 / 12
SER B  28
PHE B  33
HIS B  19
THR B  25
VAL A  42
1.68A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		4 / 6
LEU D   7
SER O  11
PHE D  60
HIS D 188
1.71A21.24
6.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 12
SER C  28
PHE C  33
HIS C  19
THR C  25
VAL P  42
1.78A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 12
SER O  11
ASN O  10
THR D   5
VAL D   4
LEU D  27
1.39A16.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		6 / 9
VAL P 108
LEU P  75
ALA P  24
ASP P  22
VAL P  13
ILE P  38
1.43A16.62
14.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 6
SER B  79
PHE B  80
ASP B  77
HIS B 172
1.67A24.21
7.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5tl7 UBIQUITIN-LIKE
PROTEIN ISG15
(Mus
musculus)		5 / 9
LEU A 105
ASP A 131
VAL A  84
HIS A 149
ILE A  82
1.46A11.49
20.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
SER C 703
THR C1048
LEU C1045
ILE C 916
SER C 919
1.52A10.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 6
LEU A 235
PHE A  76
ASP A  77
TRP A 245
1.71A14.26
3.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5x5c S PROTEIN
(MERS-CoV)		4 / 6
LEU A 324
SER A 353
PHE A 354
ASP A 355
1.46A14.30
2.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER B 703
THR B 705
LEU B1045
ILE B 913
SER B 914
1.60A10.81
SER  B 703 ( 0.0A)
THR  B 705 ( 0.8A)
LEU  B1045 ( 0.6A)
ILE  B 913 ( 0.4A)
SER  B 914 ( 0.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
LEU A 948
SER B 556
PHE B 558
ASP B 554
1.55A15.07
3.44
LEU  A 948 ( 0.6A)
SER  B 556 ( 0.0A)
PHE  B 558 ( 1.3A)
ASP  B 554 ( 0.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 6
SER A  79
PHE A  80
ASP A  77
HIS A 172
1.62A23.82
11.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6acg ACE2
(Homo
sapiens)		5 / 12
ASN D  33
THR D  92
VAL D  93
GLN D  96
LEU D  97
0.90A15.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6acg ACE2
(Homo
sapiens)		5 / 12
PRO D 583
THR D 519
GLN D 522
ILE D 407
SER D 411
1.61A15.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER A 703
THR A1048
LEU A1045
ILE A 916
SER A 919
1.30A10.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6acj ACE2
(Homo
sapiens)		4 / 6
LEU D 410
SER D 411
ASP D 543
HIS D 540
1.55A21.63
4.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
SER A 303
ASN C 746
VAL A 581
GLN A 301
SER C 717
1.75A10.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
LEU B 355
SER B 353
PHE B 325
ASP B 351
1.47A14.91
3.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6cs0 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
ASN A 118
THR A 236
VAL A 140
GLN A 147
SER A 169
1.56A10.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
THR C 809
VAL C 808
GLN C 931
LEU C 930
SER C 924
1.53A10.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6cs2 ACE2
(Homo
sapiens)		5 / 12
ASN D  33
THR D  92
VAL D  93
GLN D  96
LEU D  97
0.88A15.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6cs2 ACE2
(Homo
sapiens)		4 / 6
LEU D 333
PHE D 308
ASP D 303
TRP D 328
1.73A21.88
4.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6lzg SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU B 425
PHE B 429
ASP B 428
VAL B 433
ILE B 410
1.49A20.00
13.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m18 ACE2
(Homo
sapiens)		5 / 12
ASN D  33
THR D  92
VAL D  93
GLN D  96
LEU D  97
0.97A13.13
None
NAG  D 903 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m71 NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.74A12.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6m71 NSP8
(SARS-CoV-2)		5 / 9
LEU B 180
ALA B 181
ASP B 163
VAL B 159
ILE B 172
1.61A20.81

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6m71 NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.46A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		5 / 12
SER L 181
THR L 183
VAL L 137
ILE L 122
SER H 144
1.63A22.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6nur NSP12
(SARSr-CoV)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.44A18.09
4.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
ASN A 955
VAL A1008
GLN A1011
LEU A1012
ILE A 770
1.47A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.62A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vw1 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU E 425
PHE E 429
ASP E 428
VAL E 433
ILE E 410
1.48A20.35
14.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vw1 ACE2
(Homo
sapiens)		5 / 12
ASN A  33
THR A  92
VAL A  93
GLN A  96
LEU A  97
0.92A15.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxs NSP3
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.69A
SO4  B 204 (-3.7A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxs NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.64A
SO4  A 203 (-4.0A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
HIS A 519
THR A 547
LEU B 981
ILE B 980
SER B 974
1.54A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER C1055
PRO C 807
THR C 874
GLN C1054
ILE C 818
1.64A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU A 425
PHE A 429
ASP A 428
VAL A 433
ILE A 410
1.44A15.90
3.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU C 425
PHE C 429
ASP C 428
VAL C 433
ILE C 410
1.37A15.90
3.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
SER A1055
PRO A 807
THR A 874
GLN A1054
ILE A 818
1.69A10.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
LEU B 298
ILE B 323
1.32A19.46
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.52A19.46
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
EDO  B 403 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w37 PROTEIN 7A
(SARS-CoV-2)		5 / 12
HIS A  32
PHE A  31
THR A  13
VAL A  14
LEU A  62
1.56A14.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		5 / 9
LEU C 425
PHE C 429
ASP C 428
VAL C 433
ILE C 410
1.47A19.71
13.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w4h NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.30A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w61 NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.42A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.69A17.63
14.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w6y NSP3
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.67A19.07
12.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w6y NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.71A19.07
12.34
AMP  A 201 ( 4.4A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP16
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.71A17.11
14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP16
(SARS-CoV-2)		5 / 9
LEU C6883
ALA C6881
ASP C6904
VAL C6865
ILE C6926
1.71A17.11
14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP16
(SARS-CoV-2)		5 / 9
VAL A7092
LEU C6909
ASP C6900
VAL C6894
ILE C7088
1.45A17.11
14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP10
(SARS-CoV-2)		5 / 9
VAL D4361
LEU D4328
ALA D4277
ASP D4275
ILE D4291
1.31A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP10
NSP16
(SARS-CoV-2)		4 / 6
LEU C6909
SER C6896
ASP C6895
HIS D4333
1.79A16.98
15.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6w75 NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.31A15.99
9.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.73A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wcf NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wen NSP3
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wey NSP3
(SARS-CoV-2)		5 / 9
VAL A 359
LEU A 344
ASP A 339
VAL A 369
ILE A 222
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU C6883
ALA C6881
ASP C6904
VAL C6865
ILE C6926
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt NSP10
(SARS-CoV-2)		5 / 9
VAL D4361
LEU D4328
ALA D4277
ASP D4275
ILE D4291
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
VAL A7092
LEU C6909
ASP C6900
VAL C6894
ILE C7088
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 6
LEU A6909
SER A6896
ASP A6895
HIS B4333
1.72A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 6
LEU C6909
SER C6896
ASP C6895
HIS D4333
1.73A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wjt NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 12
HIS B  59
SER B 105
THR C 141
ILE C 146
SER C  78
1.79A
 ZN  C 201 (-3.3A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP16
(SARS-CoV-2)		5 / 9
LEU C6883
ALA C6881
ASP C6904
VAL C6865
ILE C6926
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 6
LEU A6909
SER A6896
ASP A6895
HIS B4333
1.79A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP16
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
NSP16
(SARS-CoV-2)		4 / 6
LEU C6909
SER C6896
ASP C6895
HIS D4333
1.79A22.31
9.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP16
(SARS-CoV-2)		5 / 9
VAL A7092
LEU C6909
ASP C6900
VAL C6894
ILE C7088
1.46A
 NA  A7102 ( 4.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wkq NSP10
(SARS-CoV-2)		5 / 9
VAL D4361
LEU D4328
ALA D4277
ASP D4275
ILE D4291
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
LEU B 298
ILE B 323
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER A 274
ASN A  75
PRO A 344
LEU A 298
ILE A 323
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
VAL D 155
LEU D 140
ASP D 135
VAL D 165
ILE D  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 9
LEU A6883
ALA A6881
ASP A6904
VAL A6865
ILE A6926
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2O7O_A_DXTA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6wq3 NSP10
(SARS-CoV-2)		5 / 9
VAL B4361
LEU B4328
ALA B4277
ASP B4275
ILE B4291
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU A 425
PHE A 429
ASP A 428
VAL A 433
ILE A 410
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU E 425
PHE E 429
ASP E 428
VAL E 433
ILE E 410
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU E 425
PHE E 429
ASP E 428
VAL E 433
ILE E 410
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU E 425
PHE E 429
ASP E 428
VAL E 433
ILE E 410
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
LEU A 425
PHE A 429
ASP A 428
VAL A 433
ILE A 410
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL E 155
LEU E 140
ASP E 135
VAL E 165
ILE E  18
1.69A
EDO  E 205 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL D 155
LEU D 140
ASP D 135
VAL D 165
ILE D  18
1.68A
EDO  D 208 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL D 155
LEU D 140
ASP D 135
VAL D 165
ILE D  18
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL E 155
LEU E 140
ASP E 135
VAL E 165
ILE E  18
1.69A
APR  E 201 ( 4.9A)
None
EDO  B 202 (-4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.65A
APR  A 201 ( 4.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 126
ALA A 129
ASP A 135
ILE A  18
1.76A
APR  A 201 ( 4.8A)
APR  A 201 (-4.8A)
APR  A 201 ( 3.7A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.69A
APR  C 201 ( 4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL B 155
LEU B 140
ASP B 135
VAL B 165
ILE B  18
1.72A
EDO  B 202 (-4.0A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL C 155
LEU C 140
ASP C 135
VAL C 165
ILE C  18
1.68A
EDO  C 206 ( 4.2A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM2_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 9
VAL A 155
LEU A 140
ASP A 135
VAL A 165
ILE A  18
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 6
LEU A 437
SER C   4
PHE A 429
ASP C   5
1.74A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7btf NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.46A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
ASN A 507
PHE A 506
LEU A 673
ILE A 539
SER A 561
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
HIS A 816
HIS A 872
VAL A 435
LEU A 838
ILE A 837
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7btf NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7btf NSP12
(SARS-CoV-2)		4 / 6
LEU A 241
ASP A 465
HIS A 309
TRP A 290
1.75A17.47
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
ASN A 507
PHE A 506
LEU A 673
ILE A 539
SER A 561
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP12
NSP7
(SARS-CoV-2)		4 / 6
LEU A 437
SER C   4
PHE A 429
ASP C   5
1.78A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.46A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
LEU A 241
ASP A 465
HIS A 309
TRP A 290
1.76A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
LEU A 245
ASP A 465
HIS A 309
TRP A 290
1.50A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5OM3_B_DXTB501_1
(ALPHA-1-ANTICHYMOTRY
PSIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
LEU A 241
ASP A 465
HIS A 309
TRP A 290
1.68A17.60
4.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2XRL_A_DXTA1211_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
HIS A 133
THR A 701
VAL A 704
GLN A 468
LEU A 731
1.73A
None